drugset / Trial / NCT01302106

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes

NCT01302106

NaSingle-groupOpen-labelTreatment

Summary

This is an interventional, multicenter, open label, phase II study designed to evaluate the safety and efficacy of Clofarabine in combination with low dose Cytarabine in untreated patients with poor risk of Myelodisplastic Syndromes.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 10 mg/m2 Intravenous
Subject Cytarabine Small molecule 10 mg/m2 Subcutaneous